ClinicalTrials.gg
CompletedNCT05153317Updated Mar 3, 2026

Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis (CF) Participants 2 Years and Older

A Phase 3 interventional study of ELX/TEZ/IVA and IVA in Cystic Fibrosis, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 22 sites in 5 countries. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2026-03-03.

Sponsored by Vertex Pharmaceuticals Incorporated · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
71
Allocation
Not applicable
Ages
2 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies testing elexacaftor in Cystic Fibrosis — 2 open to participants now, 5 under way, 2 of them phase 3. elexacaftor · Cystic Fibrosis.

Enrollment
17th of 23
71 · median 120
Started
2022
with 3 others
Phase 3
19 of 23
none open now
Registered
17th of 23
by date
Lead sponsor
20 of 23
Vertex Pharmaceuticals Incorporated

Among the 23 studies testing elexacaftor in Cystic Fibrosis, this one is the 17th largest by enrollment, is one of 4 that started in 2022, is one of 19 in phase 3, and was the 17th registered.

Cystic Fibrosis

1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.

Browse Cystic Fibrosis studies →

Open to participants now

2 of the 23 studies testing elexacaftor in Cystic Fibrosis are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About elexacaftor

elexacaftor: first FDA approval 2019 (TRIKAFTA (COPACKAGED)), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.

This study: 2 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing elexacaftor in Cystic Fibrosis, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the long term safety, tolerability, efficacy and pharmacodynamics of elexacaftor (ELX)/tezacaftor (TEZ)/ivacaftor (IVA) in CF participants 2 years of age and older.

03

Conditions studied

  • Cystic Fibrosis

Browse trials for

04

Who can participate

Ages eligible
2 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

key Inclusion Criteria:

  • Completed study drug treatment in the parent study (VX20-445-111 Part B, NCT04537793), or had study drug interruption(s) in the parent study, but did not permanently discontinue study drug, and completed study visits up to the last scheduled visit of the Treatment Period of the parent study

Key Exclusion Criteria:

  • History of study drug intolerance in the parent study
  • History of poor compliance with ELX/TEZ/IVA and/or procedures in the parent study

Other protocol defined Inclusion/Exclusion criteria may apply

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
71 participants (actual)

Study arms

  • Experimental
    ELX/TEZ/IVA

    Participants will receive ELX/TEZ/IVA in the morning and IVA in the evening.

    Drug: ELX/TEZ/IVA · Drug: IVA

Interventions

  • DrugELX/TEZ/IVA

    Drug pages: Elexacaftor · Tezacaftor · Ivacaftor

    Fixed-dose combination granules or tablets for oral administration.

    Also known as: VX-445/VX-661/VX-770, elexacaftor/tezacaftor/ivacaftor

  • DrugIVA

    Granules or tablets for oral administration.

    Also known as: VX-770, ivacaftor

06

What researchers measure

Primary outcomes

  1. Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Time frame: From Day 1 up to Week 196

Secondary outcomes

  1. Absolute Change in Sweat Chloride (SwCl)

    Time frame: From Baseline up to Week 192

  2. Absolute Change in Lung Clearance Index (LCI) 2.5

    Time frame: From Baseline up to Week 192

07

Study locations

22 sites
  • Banner University of Arizona Medical Center
    Tucson, Arizona 85724, United States
  • Stanford University
    Palo Alto, California 94304, United States
  • Children's Hospital of Colorado
    Aurora, Colorado 80045, United States
  • Ann & Robert H. Lurie Children's Hospital of Chicago
    Chicago, Illinois 60611, United States
  • Riley Hospital for Children at Indiana University Health
    Indianapolis, Indiana 46202, United States
  • Boston Children's Hospital
    Boston, Massachusetts 02115, United States
  • Children's Respiratory and Critical Care Specialists, P.A., Children's Hospitals and Clinics of Minnesota
    Minneapolis, Minnesota 55404, United States
  • The Children's Mercy Hospital
    Kansas City, Missouri 64108, United States
  • Washington University School of Medicine / St. Louis Children's Hospital
    St Louis, Missouri 63110, United States
  • NC TraCS Institute - CTRC University of North Carolina at Chapel Hill
    Chapel Hill, North Carolina 27599, United States
  • Oregon Health & Science University
    Portland, Oregon 97239, United States
  • UPMC Children's Hospital of Pittsburgh
    Pittsburgh, Pennsylvania 15224, United States
  • Seattle Children's Hospital
    Seattle, Washington 98105, United States
  • Telethon Kids Institute
    Nedlands, Australia
  • The Royal Children's Hospital
    Parkville, Australia
  • Queensland Children's Hospital
    South Brisbane, Australia
  • The Hospital for Sick Children
    Toronto, Canada
  • British Columbia Children's Hospital
    Vancouver, Canada
  • Charite Paediatric Pulmonology Department
    Berlin, Germany
  • Universitatsklinikum Essen (AoR), Kinderklinik III, Abt. fur Pneumologie
    Essen, Germany
  • Alder Hey Children's NHS Foundation Trust
    Liverpool, United Kingdom
  • Royal Brompton Hospital
    London, United Kingdom
08

References and documents

Individual participant data

Plan to share: No — Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/our-science/clinical-trials-data-sharing/

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2022 to primary completion in Jan 2026, 48 months.

Of 58 industry-sponsored phase 3 interventional studies under Cystic Fibrosis, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 36. This study's 48 months is above that.

Counting every sponsor, half of 67 studies reached it within 26 months; a quarter within 16 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 29, 2021
First posted
Dec 10, 2021
StartActual
Jan 17, 2022
Primary completionActual
Jan 29, 2026
CompletionActual
Jan 29, 2026
Last update
Mar 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05153317
Responsible party
Sponsor
First posted
Dec 10, 2021
Start date
Jan 17, 2022
Primary completion
Jan 29, 2026
Completion
Jan 29, 2026
Last update
Mar 3, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Elexacaftor · Tezacaftor · Ivacaftor

Start the discussion